Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Diagnostics: David Patience, Steve Reichling

Accelerate Diagnostics has named David Patience as its new CFO, effective April 1. He replaces Steve Reichling, who is stepping down to pursue other opportunities. Patience was previously senior director, head of business development and strategic finance at Accelerate. Prior to that, he was director, head of finance, planning and analysis and corporate development. Before joining Accelerate, Patience was with Morgan Stanley's investment banking division. He was also in equity research at Continental Advisors and held various financial research roles at Nuveen Investments. Reichling has been with Accelerate since 2012 and will remain in a consulting role with the firm through 2023.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.